Dividend Investing Ideas Center
Critical Facts You Need to Know About Preferred Stocks
Have you ever wished for the safety of bonds, but the return potential...
You take care of your investments. We like that.
Upgrade to Premium to access your Watchlist and more.
iShares Genomics Immunology and Healthcare ETF
ETF
IDNA
Payout Change
Pending
Price as of:
$22.1714
-0.1
-0.44%
primary theme
Health Care Sector Equity
IDNA (ETF)
iShares Genomics Immunology and Healthcare ETF
Payout Change
Pending
Price as of:
$22.1714
-0.1
-0.44%
primary theme
Health Care Sector Equity
IDNA (ETF)
iShares Genomics Immunology and Healthcare ETF
Payout Change
Pending
Price as of:
$22.1714
-0.1
-0.44%
primary theme
Health Care Sector Equity
Name
As of 04/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
Vitals
YTD Return
-3.6%
1 yr return
-4.7%
3 Yr Avg Return
-21.6%
5 Yr Avg Return
N/A
Net Assets
$140 M
Holdings in Top 10
60.7%
52 WEEK LOW AND HIGH
$22.3
$17.37
$25.20
Expenses
OPERATING FEES
Expense Ratio 0.47%
SALES FEES
Front Load N/A
Deferred Load N/A
TRADING FEES
Turnover 52.00%
Redemption Fee N/A
Min Investment
Standard (Taxable)
N/A
IRA
N/A
Fund Classification
Fund Type
Exchange Traded Fund
Name
As of 04/24/2024Price
Aum/Mkt Cap
YIELD
Annualized forward dividend yield. Multiplies the most recent dividend payout amount by its frequency and divides by the previous close price.
Exp Ratio
Expense ratio is the fund’s total annual operating expenses, including management fees, distribution fees, and other expenses, expressed as a percentage of average net assets.
Watchlist
IDNA - Profile
Distributions
- YTD Total Return -3.6%
- 3 Yr Annualized Total Return -21.6%
- 5 Yr Annualized Total Return N/A
- Capital Gain Distribution Frequency N/A
- Net Income Ratio 0.16%
- Dividend Yield 1.5%
- Dividend Distribution Frequency SemiAnnual
Fund Details
-
Legal NameiShares Genomics Immunology and Healthcare ETF
-
Fund Family NameBlackRock-advised Funds
-
Inception DateJun 11, 2019
-
Shares Outstanding6550000
-
Share ClassN/A
-
CurrencyUSD
-
Domiciled CountryUS
-
ManagerJennifer Hsui
Fund Description
The Fund seeks to track the investment results of the NYSE® FactSet® Global Genomics and Immuno Biopharma Index (the “Underlying Index”), which measures the performance of equity securities issued by companies in the biopharmaceutical and healthcare equipment and services industries that could benefit from the long-term growth and innovation in genomics, immunology and bioengineering, as determined by ICE Data Indices, LLC or its affiliates (the “Index Provider” or “IDI”). The Underlying Index is composed of equity securities primarily listed in one of 43 developed and emerging market countries. Companies must have equal to or greater than 50% of their revenue from one or more selected Level 6 industries, as defined by the FactSet Revere Business Industry Classification System (“RBICS”), which includes biopharmaceutical industries,
healthcare equipment industries, and healthcare services industries. Companies selected from these industries are assigned a Genomics and Immuno Biopharma Composite Relationship Keyword score (a “Score”). To compute a Score for a company, the Index Provider searches the FactSet Supply Chain Relationships database for keywords related to genomics and immunology products and technologies. A Score is assigned to each company identified in the database search based on the number of relationships a company has to genomics and immunology products. The top 50 companies with the highest Scores are selected for inclusion in the Underlying Index. The Underlying Index is reviewed and reconstituted annually in December. Constituent weights of the Underlying Index are determined according to float-adjusted market capitalization and are rebalanced semi-annually. Individual constituents are capped at 4% of the Underlying Index. The aggregate weight of component securities classified in the RBICS Level 6 industry Diversified Biopharmaceuticals is capped at 25%, with excess weight redistributed proportionately among remaining constituents. The Underlying Index includes large-, mid- and small-capitalization companies and may change over time. As of July 31, 2023 a significant portion of the Underlying Index is represented by securities of companies in the healthcare industry or sector. The components of the Underlying Index are likely to change over time.
BFA uses an indexing approach to try to achieve the Fund’s investment objective. Unlike many investment companies, the Fund does not try to “beat” the index it tracks and does not seek temporary defensive positions when markets decline or appear overvalued.
Indexing may eliminate the chance that the Fund will substantially outperform the Underlying Index but also may reduce some of the risks of active management, such as poor security selection. Indexing seeks to achieve lower costs and better after-tax performance by aiming to keep portfolio turnover low in comparison to actively managed investment companies.
BFA uses a representative sampling indexing strategy to manage the Fund. “Representative sampling” is an indexing strategy that involves investing in a representative sample of securities that collectively has an investment profile similar to that of an applicable underlying index. The securities selected are expected to have, in the aggregate, investment characteristics (based on factors such as market capitalization and industry weightings), fundamental characteristics (such as return variability and yield) and liquidity measures similar to those of an applicable underlying index. The Fund may or may not hold all of the securities in the Underlying Index.
The Fund generally will invest at least 80% of its assets in the component securities of its Underlying Index and in investments that have economic characteristics that are substantially identical to the component securities of its Underlying Index (i.e., depositary receipts representing securities of the Underlying Index) and may invest up to
20% of its assets in certain futures, options and swap contracts, cash and cash equivalents, including shares of money market funds advised by BFA or its affiliates, as well as in securities not included in the Underlying Index, but which BFA believes will help the Fund track the Underlying Index. Cash and cash equivalent investments associated with a derivative position will be treated as part of that position for the purposes of calculating the percentage of investments included in the Underlying Index. The Fund seeks to track the investment results of the Underlying Index before fees and expenses of the Fund.
The Fund may lend securities representing up to one-third of the value of the Fund's total assets (including the value of any collateral received).
The Underlying Index is owned, maintained and administered by the Index Provider, which is independent of the Fund and BFA. The Index Provider determines the composition and relative weightings of the securities in the Underlying Index and publishes information regarding the market value of the Underlying Index.
Industry Concentration Policy. The Fund will concentrate its investments i.e., hold 25% or more of its total assets) in a particular industry or group of industries to approximately the same extent that the Underlying Index is concentrated. For purposes of this limitation, securities of the U.S. government (including its agencies and instrumentalities) and repurchase agreements collateralized by U.S. government securities are not considered to be issued by members of any industry.
IDNA - Performance
Return Ranking - Trailing
| Period | IDNA Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.6% | -27.9% | 13.7% | 82.21% |
| 1 Yr | -4.7% | -25.0% | 20.7% | 88.96% |
| 3 Yr | -21.6%* | -35.7% | 11.5% | 97.44% |
| 5 Yr | N/A* | -7.3% | 15.0% | 52.52% |
| 10 Yr | N/A* | 0.0% | 14.0% | 74.79% |
* Annualized
Return Ranking - Calendar
| Period | IDNA Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -8.6% | -12.6% | 19.0% | 96.32% |
| 2022 | -42.5% | -53.9% | 3.2% | 99.36% |
| 2021 | -4.6% | -39.6% | 24.2% | 67.95% |
| 2020 | 53.8% | -13.6% | 178.2% | 3.31% |
| 2019 | N/A | 3.8% | 63.8% | N/A |
Total Return Ranking - Trailing
| Period | IDNA Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| YTD | -3.6% | -27.9% | 13.7% | 82.21% |
| 1 Yr | -4.7% | -25.0% | 20.7% | 88.96% |
| 3 Yr | -21.6%* | -35.7% | 11.5% | 97.44% |
| 5 Yr | N/A* | -7.3% | 15.0% | N/A |
| 10 Yr | N/A* | 0.0% | 14.0% | N/A |
* Annualized
Total Return Ranking - Calendar
| Period | IDNA Return | Category Return Low | Category Return High | Rank in Category (%) |
|---|---|---|---|---|
| 2023 | -7.6% | -12.6% | 19.0% | 96.32% |
| 2022 | -42.3% | -53.9% | 3.7% | 98.72% |
| 2021 | -4.0% | -33.9% | 26.0% | 85.26% |
| 2020 | 54.3% | -0.7% | 180.6% | 5.30% |
| 2019 | N/A | 4.6% | 63.8% | N/A |
IDNA - Holdings
Concentration Analysis
| IDNA | Category Low | Category High | IDNA % Rank | |
|---|---|---|---|---|
| Net Assets | 140 M | 7.41 M | 47.2 B | 71.17% |
| Number of Holdings | 55 | 23 | 413 | 77.30% |
| Net Assets in Top 10 | 74.9 M | 2.19 M | 20.5 B | 66.87% |
| Weighting of Top 10 | 60.72% | 18.1% | 77.0% | 10.43% |
Top 10 Holdings
- BlackRock Cash Funds: Institutional, SL Agency Shares 21.20%
- Sarepta Therapeutics Inc 5.34%
- Moderna Inc 4.80%
- Merck Co Inc 4.42%
- Regeneron Pharmaceuticals Inc 4.38%
- REVOLUTION Medicines Inc 4.29%
- GSK PLC 4.13%
- Incyte Corp 4.12%
- Sanofi SA 4.09%
- Takeda Pharmaceutical Co Ltd 3.95%
Asset Allocation
| Weighting | Return Low | Return High | IDNA % Rank | |
|---|---|---|---|---|
| Stocks | 99.79% | 87.17% | 106.13% | 17.79% |
| Cash | 21.27% | 0.00% | 32.99% | 3.07% |
| Other | 0.00% | -22.99% | 17.73% | 28.22% |
| Preferred Stocks | 0.00% | 0.00% | 7.86% | 92.64% |
| Convertible Bonds | 0.00% | 0.00% | 0.37% | 91.77% |
| Bonds | 0.00% | 0.00% | 12.39% | 91.41% |
Stock Sector Breakdown
| Weighting | Return Low | Return High | IDNA % Rank | |
|---|---|---|---|---|
| Healthcare | 100.00% | 59.26% | 100.00% | 41.77% |
| Utilities | 0.00% | 0.00% | 0.00% | 91.14% |
| Technology | 0.00% | 0.00% | 22.69% | 92.41% |
| Real Estate | 0.00% | 0.00% | 5.89% | 91.77% |
| Industrials | 0.00% | 0.00% | 7.02% | 91.77% |
| Financial Services | 0.00% | 0.00% | 1.60% | 93.04% |
| Energy | 0.00% | 0.00% | 0.00% | 91.14% |
| Communication Services | 0.00% | 0.00% | 9.11% | 91.14% |
| Consumer Defense | 0.00% | 0.00% | 25.73% | 93.67% |
| Consumer Cyclical | 0.00% | 0.00% | 1.92% | 92.41% |
| Basic Materials | 0.00% | 0.00% | 7.16% | 92.41% |
Stock Geographic Breakdown
| Weighting | Return Low | Return High | IDNA % Rank | |
|---|---|---|---|---|
| US | 74.33% | 66.21% | 104.41% | 93.87% |
| Non US | 25.46% | 0.00% | 28.58% | 3.68% |
IDNA - Expenses
Operational Fees
| IDNA Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Expense Ratio | 0.47% | 0.08% | 4.28% | 87.73% |
| Management Fee | 0.47% | 0.03% | 1.25% | 13.50% |
| 12b-1 Fee | N/A | 0.00% | 1.00% | N/A |
| Administrative Fee | N/A | 0.03% | 0.25% | N/A |
Sales Fees
| IDNA Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Front Load | N/A | 3.50% | 5.75% | N/A |
| Deferred Load | N/A | 1.00% | 5.00% | N/A |
Trading Fees
| IDNA Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Max Redemption Fee | N/A | 1.00% | 1.00% | N/A |
Related Fees
Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.
| IDNA Fees (% of AUM) | Category Return Low | Category Return High | Rank in Category (%) | |
|---|---|---|---|---|
| Turnover | 52.00% | 0.00% | 238.00% | 59.42% |
IDNA - Distributions
Dividend Yield Analysis
| IDNA | Category Low | Category High | IDNA % Rank | |
|---|---|---|---|---|
| Dividend Yield | 1.53% | 0.00% | 6.25% | 25.15% |
Dividend Distribution Analysis
| IDNA | Category Low | Category High | Category Mod | |
|---|---|---|---|---|
| Dividend Distribution Frequency | SemiAnnual | Annual | Quarterly | Annual |
Net Income Ratio Analysis
| IDNA | Category Low | Category High | IDNA % Rank | |
|---|---|---|---|---|
| Net Income Ratio | 0.16% | -2.54% | 1.85% | 29.49% |
Capital Gain Distribution Analysis
| IDNA | Category Low | Category High | Capital Mode | |
|---|---|---|---|---|
| Capital Gain Distribution Frequency | Annually | Annually | Annually |
Distributions History
| Date | Amount | Type |
|---|---|---|
| Dec 27, 2023 | $0.169 | OrdinaryDividend |
| Jun 13, 2023 | $0.071 | OrdinaryDividend |
| Jun 15, 2022 | $0.136 | OrdinaryDividend |
| Dec 17, 2021 | $0.256 | OrdinaryDividend |
| Jun 16, 2021 | $0.052 | OrdinaryDividend |
| Dec 18, 2020 | $0.036 | OrdinaryDividend |
| Jun 19, 2020 | $0.084 | OrdinaryDividend |
IDNA - Fund Manager Analysis
Managers
Jennifer Hsui
Start Date
Tenure
Tenure Rank
Jun 11, 2019
2.97
3.0%
Jennifer Hsui, Managing Director & Portfolio Manager at BlackRock Investment Management LLC has been employed by BlackRock Fund Advisors as a senior portfolio manager since 2007. Prior to that, Ms. Hsui was a portfolio manager from 2006 to 2007 for BGFA. She was a research analyst for RBC Capital Markets from 2003 to 2006.
Amy Whitelaw
Start Date
Tenure
Tenure Rank
Jun 11, 2019
2.97
3.0%
Amy Whitelaw is Managing Director of BlackRock, Inc. since 2013 and was Director of the firm from 2009 to 2012. Ms. Whitelaw's service with the firm dates back to 1998, including her years with Barclays Global Investors (BGI), which merged with BlackRock in 2009. Ms. Whitelaw served as Principal of BGI from 2000 to 2009. Previously Ms. Whitelaw worked in the Transition Services group as a transition manager and strategist, and was also an international equity trader on BGI’s trading desk.
Greg Savage
Start Date
Tenure
Tenure Rank
Jun 11, 2019
2.97
3.0%
Greg Savage, Managing Director; has been associated with BlackRock Fund Advisors since 2009. Mr. Savage has been a senior portfolio manager for BFA and BTC since 2009. Prior to his employment with BFA and BTC, Mr. Savage was a senior portfolio manager from 2006 to 2009 for BGFA and BGI and a portfolio manager from 2001 to 2006 for BGFA and BGI.
Paul Whitehead
Start Date
Tenure
Tenure Rank
Jan 01, 2022
0.41
0.4%
Paul Whitehead is responsible for supporting the day-to-day management of the MML Blend Fund’s portfolio, including setting the Fund’s overall investment strategy and overseeing the management of the Fund. Mr. Whitehead is a Managing Director of BlackRock, Inc., Co-Head of Index Equity, and Co-Head of BlackRock’s ETF and Index Investments business. Mr. Whitehead also oversees the management of BlackRock’s Institutional and iShares funds. Mr. Whitehead was previously the Global Head of Equity Trading and the Global Head of Transition Management within BlackRock’s Global Trading Group. Mr. Whitehead’s service with the firm dates back to 1996, including his years with Barclays Global Investors, which merged with BlackRock in 2009. Prior to his current role, Mr. Whitehead was Head of Americas Equity Trading. Previously, he managed the trading team responsible for all Institutional Index funds, Exchange Traded funds, and Transition Management mandates. Mr. Whitehead represents BlackRock on the board of Luminex, a buy-side owned Alternative Trading System launched in 2015.
Tenure Analysis
| Category Low | Category High | Category Average | Category Mode |
|---|---|---|---|
| 0.02 | 24.72 | 7.84 | 0.25 |
